TA Associates’ Post

At Cavendish, we believe AIM is a great platform for owners of businesses as it allows them to source additional capital whilst maintaining an element of control.  It also allows the flexibility for the founders to sell down their stakes in a controlled manner.     Cavendish has been involved in managing multiple sell downs over recent years and completed two in life sciences in last month, realising £11m in aggregate, both at a discount of less than 5% to the mid price.   This is despite ongoing challenges in equity markets.  These two sell downs, in Bioventix (£2.4m) and hVIVO (£8.4m) were both oversubscribed and allowed us to introduce a number of high quality investors to the register.       Geoff Nash, Corporate Finance Director commented: “We have an ongoing desire to broaden the shareholder base of all our corporate clients and were pleased to be able to do so for both of these fantastic businesses – we brought Bioventix to AIM with a market cap of £28m (now £260m) and started working with hVIVO (then Open Orphan) in mid-2020 when the market capitalisation was £70m (£180m today). If we can help your business, please do get in touch.” #lifesciences #healthcare #growthbusiness #capitalmarkets #AIM

Two great examples of our clients’ continued growth stories on AIM and how recent sell downs have broadened the shareholder base for these firms. #growthbusiness #capitalmarkets #ukeconomy

Delighted to announce our Gold Partner, NovaQuest Capital Management at our upcoming #ALTSLA in Los Angeles on March 18 & 20, 2024. NovaQuest Capital Management is a specialist life sciences investment firm founded in 2010 by a team of accomplished in-dustry professionals. NovaQuest pioneered a PRODUCT FINANCEcapital solution for the industry, providing shared-risk, non-dilutive funding that enables partner companies to advance pivotal clinical trials, launch new brands, and license and acquire accretive products. NovaQuest makes unlevered investments, generally through self-liquidating structures, yielding return streams uncorrelated to broad equity and fixed income markets. With more than $2.5 billion raised across four funds, NovaQuest main-tains investment platforms in human and animal health verticals.    For more information on the event, please visit https://altsla.com/    #CFA, #CAIAAssociation, #CalALTS, #ALTSLA, #ALTSLA24 #MarketsGroup #alternativeinvestments Kareen Mozes Laton Patrick Jordan Michael Bologna Paul Hamann Debra Haym

I am confident to say, that in 2023 at ZAKA VC we didn’t lose our momentum. We simply continued our way, following our investment strategy and further developing our know-how. We’ve also strengthened our position in healthcare & biotech part of our portfolio with 8 investments altogether. It’s beginning to look like a speciality of ours and it’s definitely not a coincidence. It seems that so far, it’s been a year of good decisions. I hope that new one will follow the same path. #yearinreview #2023 #venturecapital #zaka 

Sidetrade discussed in detail the highly promising acquisition of SHS Viveon. This deal once again confirms Sidetrade's ability to seize M&A opportunities likely to boost its organic growth potential at prices far removed from market standards. #SidetradeALeader

Life Sciences Commentary Geoff Nash, Director at Cavendish comments: "We all look forward to a more positive 2024 after two of most challenging years in equity markets ever experienced.  Despite this, at Cavendish we continue to deliver for our clients. Since January 2022 we have raised over £105m across 13 secondaries and an IPO in feed additives. This represents over 25% of all activity in the life sciences sector where approximately £400m* was raised in 2022/3. We have lots to execute on in 2024 and look forward to growing our healthcare franchise further.”   *excludes fundings sub £2m #lifesciences #healthcare #growthbusiness #capitalmarkets

➖ CAPITAL RAISE ➖   Adherium has announced a $8.37 million capital raising via a Placement and Non-Renounceable Entitlement Offer.    The Company has received firm commitments for a capital raising of up to $1.57 million before costs, by way of a placement of new shares to sophisticated and professional investors. The placement will be undertaken in two tranches with the second tranche including CEO and Director participation.    Adherium also proposes to undertake a fully underwritten non-renounceable entitlement offer of new shares and new options to eligible shareholders to raise up to $6.8 million before costs.    These funds will be used to fast track US commercialisation of Adherium’s Hailie® Smartinhaler® technology – with multiple FDA clearances and US reimbursement codes now in place.    Adherium CEO, Dr. Paul Mastoridis, said:     “Adherium is entering a defining phase in its commercial development. We are extending the reach and impact of our world-class respiratory health product portfolio within the US, the largest healthcare market in the world. Our Company has a clear and focused US engagement and market penetration strategy, which prioritises manufacturing activities and sales via established pharmaceutical and payor groups in this market.”    For more information, read the ASX release 👉 https://lnkd.in/gs-8BXZX      $ADR #ADR #Adherium #digitalhealth #ehealth #innovation #invest #capitalraise 

The Indian IPO market has been experiencing significant activity, drawing widespread attention. Excitement and anticipation are palpable among investors. #IndianIPOs #MarketBuzz Industries like infrastructure, fintech, e-commerce, and pharma are at the forefront of this surge. These sectors are promising substantial growth and innovation. #IndustryLeaders #EconomicGrowth Participation by global investors, including both individuals and corporations, is being actively encouraged. This inclusive approach is opening new doors for international collaboration. #GlobalInvesting #InclusiveGrowth

Are you using Prendio? Recently I’ve run into 4 or 5 people who have said they don’t need to talk to Excedr because they have Prendio…. But that’s not what Prendio does! They rock, we love them, they’re one of our partners. And they are THE TOOL for Biotech/Life Sciences procurement. They can help you identify the right manufacturer for your next equipment purchase. But what they don’t do… Is handle the financing. Which is where Excedr would potentially fit into the picture, with one of our equipment leasing options. We work together, more like peanut butter and jelly. So if you’re using Prendio, rock on! And when you find the equipment of your dreams… it might be worth a chat to see if a lease would make sense for your financing. 😉 #lifesciences #biotechnology

Exciting Times in Biotech! 🧬 Neumora and RayzeBio are both diving into the IPO waters this fall, aiming to raise over $200 million each. 🚀 Neumora is offering 14,710,000 shares in the range of $16 to $18 apiece, potentially raising a whopping $250 million at the midpoint. 🔬📈 RayzeBio, on the other hand, is planning to make waves with 13,235,000 shares also in the $16 to $18 range, targeting around $225 million at the midpoint. 🌊🔍 Neumora, backed by Amgen and Arch Venture Partners, is on a mission to discover groundbreaking treatments for brain diseases, and they've got a valuation in mind of up to $2.74 billion! 🧠💊 RayzeBio is bringing its radiopharmaceuticals pipeline to the stage, with its lead program, RYZ101, in phase 3 development for gastroenteropancreatic neuroendocrine tumors. 🏥📊 These bold moves reflect a reawakening in the IPO market for biotechs, suggesting a renewed appetite for innovation. #ipo #ipoalert #news #opportunity #healthcare #biotech #innovation #investing Learn more: https://lnkd.in/dnHEk6uD